These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 38518167)
41. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer. Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586 [TBL] [Abstract][Full Text] [Related]
42. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts. Li Z; Li Y; Liu L; Zhang C; Li X Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272 [TBL] [Abstract][Full Text] [Related]
43. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748 [TBL] [Abstract][Full Text] [Related]
44. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer. Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733 [TBL] [Abstract][Full Text] [Related]
45. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
46. Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity. Zhou J; Zhou R; Zhu Y; Deng S; Muhuitijiang B; Li C; Shi X; Zhang L; Tan W J Exp Clin Cancer Res; 2024 Apr; 43(1):101. PubMed ID: 38566204 [TBL] [Abstract][Full Text] [Related]
47. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer. Zheng F; Wang Z; Li S; Xiong S; Yuan Y; Zeng J; Tan Y; Liu X; Xu S; Fu B Eur J Med Res; 2024 Jul; 29(1):393. PubMed ID: 39075554 [TBL] [Abstract][Full Text] [Related]
48. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer. Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981 [TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target. Chen D; Cao H; Zheng X; Wang H; Han Z; Wang W BMC Cancer; 2024 Aug; 24(1):1024. PubMed ID: 39160525 [TBL] [Abstract][Full Text] [Related]
50. A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer. Chen X; Liao C; Zou X; Zhang B; Mo Z Clin Transl Oncol; 2024 Feb; 26(2):477-495. PubMed ID: 37594617 [TBL] [Abstract][Full Text] [Related]
51. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Qiu H; Hu X; He C; Yu B; Li Y; Li J Front Genet; 2020; 11():12. PubMed ID: 32117435 [TBL] [Abstract][Full Text] [Related]
52. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB. Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S Front Immunol; 2023; 14():1253586. PubMed ID: 37790935 [TBL] [Abstract][Full Text] [Related]
53. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465 [TBL] [Abstract][Full Text] [Related]
54. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X Front Immunol; 2021; 12():725223. PubMed ID: 34484235 [TBL] [Abstract][Full Text] [Related]
55. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405 [TBL] [Abstract][Full Text] [Related]
56. Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma. Zhou G; Qin G; Zhang Z; Zhao H; Xue L Front Immunol; 2023; 14():1283792. PubMed ID: 37954600 [TBL] [Abstract][Full Text] [Related]
57. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer. Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059 [TBL] [Abstract][Full Text] [Related]
58. Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer. Qin R; Ma X; Pu S; Shen C; Hu D; Liu C; Wang K; Wang Y Investig Clin Urol; 2024 May; 65(3):263-278. PubMed ID: 38714517 [TBL] [Abstract][Full Text] [Related]
59. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer. Wu T; Li S; Yu C; Wu Y; Long H Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838 [TBL] [Abstract][Full Text] [Related]
60. Identification of a pyroptosis-related prognostic signature in breast cancer. Chen H; Luo H; Wang J; Li J; Jiang Y BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]